Switching from natalizumab to anti-CD20 monoclonal antibodies: optimal timing and safety analysis

被引：0
|
作者：
Levin, S. [1 ]
Levine, L. [1 ]
Vargas, W. [1 ]
Straus-Farber, R. [1 ]
De Jager, P. [1 ]
Riley, C. [1 ]
机构：
[1] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P670
引用
收藏
页码：333 / 333
页数：1
相关论文
共 50 条
  • [21] Effectiveness of anti-CD20 therapies after natalizumab
    Cunha, Carolina
    Matos, Sara
    Carvalho, Ines V.
    Cardoso, Joao
    Campelo, Isabel
    Feio, Jose
    Batista, Sonia
    Nunes, Carla
    Macario, Maria do Carmo
    Sousa, Livia Maria
    Correia, Ines
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 623 - 623
  • [22] Place of monoclonal antibodies (anti-CD52, anti-CD20) in chronic lymphocytic leukemia
    Divine, Marine
    [J]. HEMATOLOGIE, 2006, 12 : 35 - 38
  • [23] All anti-CD20 monoclonal antibodies have similar efficacy and risks: No
    Sellebjerg, Finn
    Christensen, Jeppe Romme
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (12) : 1845 - 1846
  • [24] The role of antigenic modulation in controlling the efficacy of anti-CD20 monoclonal antibodies
    Beers, S. A.
    Chan, C. H. T.
    James, S.
    French, R. R.
    Attfield, K. E.
    Brennand, C. M.
    Ahuja, A.
    Shlomchik, M.
    Cragg, M. S.
    Glennie, M. J.
    [J]. IMMUNOLOGY, 2008, 125 : 48 - 49
  • [25] Monoclonal anti-CD20 antibodies: Mechanisms of action and monitoring of biological effects
    Renaudineau, Yves
    Devauchelle-Pensec, Valerie
    Hanrotel, Catherine
    Pers, Jacques-Olivier
    Saraux, Alain
    Youinou, Pierre
    [J]. JOINT BONE SPINE, 2009, 76 (05) : 458 - 463
  • [26] Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
    Okroj, Marcin
    Osterborg, Anders
    Blom, Anna M.
    [J]. CANCER TREATMENT REVIEWS, 2013, 39 (06) : 632 - 639
  • [27] Anti-CD20 monoclonal antibodies and their use in adult autoimmune hematological disorders
    Dierickx, Daan
    Delannoy, Andre
    Saja, Khalid
    Verhoef, Gregor
    Provan, Drew
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2011, 86 (03) : 278 - 291
  • [28] The latest developments with anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia
    Evers, Mitchell
    Jak, Margot
    Leusen, J. H. W.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (09) : 973 - 982
  • [29] Is there a role for anti-CD20 antibodies in CLL?
    Shah, Harsh R.
    Stephens, Deborah M.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2021, (01) : 68 - 75
  • [30] Comparative Safety Analysis of Currently Approved Anti-CD20 Monoclonal Antibodies for First Line Treatment of Chronic Lymphocytic Leukemia (CLL)
    Mwamburi, Mkaya
    Bal, Vasudha
    Cascella, Teresa
    Shah, Anshul
    Nanavaty, Merena
    Gala, Smeet
    [J]. BLOOD, 2016, 128 (22)
12345